
Maryam B. Lustberg
Articles
-
Jul 11, 2024 |
oncodaily.com | Ian R Kleckner |Maryam B. Lustberg
Ian Kleckner, Associate Professor at the University of Maryland Baltimore, shared on X:“Our commentary on a new study suggesting exercise can improve chemo induced neuropathyMoving to a future of studying how to optimize and disseminate exercise. ”“Exercise and Physical Medicine Interventions for Managing Chemotherapy-Induced Peripheral Neuropathy‘ published in JAMA Internal Medicine.
Exercise and Physical Medicine Interventions for Managing Chemotherapy-Induced Peripheral Neuropathy
Jul 1, 2024 |
jamanetwork.com | Arjun Gupta |Ian R Kleckner |Maryam B. Lustberg
Exercise and Physical Medicine Interventions for Managing Chemotherapy-Induced Peripheral Neuropathy Preventive Effect of Neuromuscular Training on Chemotherapy-Induced Neuropathy Fiona Streckmann, PhD; Thomas Elter, PD; Helmar C.
-
Dec 7, 2023 |
newswise.com | Maryam B. Lustberg
The targeted therapy trastuzumab deruxtecan (T-Dxd), an antibody drug conjugate, is now an approved treatment of HER2-low advanced breast cancers. In a new study led by Yale Cancer Center researchers at Yale School of Medicine, their findings revealed important differences in the genetic makeup of HER2-low advanced breast cancers — a discovery that could lead to better treatment options for patients.
-
Nov 29, 2023 |
newswise.com | Eric S. Winer |Maryam B. Lustberg
Yale Cancer Center researchers at Yale School of Medicine will present new research at the 46th annual San Antonio Breast Cancer Symposium (SABCS) from December 5 to 9. The international symposium provides leading-edge breast cancer information on prevention, etiology, diagnosis, and therapy as well as experimental biology. This year’s symposium, at the Henry B. Gonzalez Convention Center, will include about 10,000 clinicians, scientists, patient advocates, and health care professionals.
-
Jun 26, 2023 |
caledonianrecord.com | Maryam B. Lustberg
MONDAY, June 26, 2023 (HealthDay News) -- Metastatic breast cancer can be a daunting diagnosis, but the prognosis has improved somewhat with advances in treatment.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →